利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.022 秒)

    Sustainable method for synthesizing tetrodotoxin (TTX)
    1.
    发明申请
    Sustainable method for synthesizing tetrodotoxin (TTX) 审中-公开
    合成河豚毒素（TTX）的可持续方法

    公开(公告)号：US20110081690A1

    公开(公告)日：2011-04-07

    申请号：US12924302

    申请日：2010-09-24

    申请人： Malin Strand ,  Per Sundberg

    发明人： Malin Strand ,  Per Sundberg

    IPC分类号： C12P17/18

    CPC分类号： C12P17/188 ,  C12N1/20 ,  C12R1/63

    摘要： A sustainable biosynthesizing of tetrodotoxin (TTX) based on seed culture of Vibrio spp is obtained from the mucus of various species of nemerteans (ribbon worms) (phylum Nemertea). The indispensable organisms are kept alive which extends access to crude material and makes the procedure economically and ecologically sustainable.

    摘要翻译： 基于不同种类的nemerteans（丝带虫）（Nemertea）的粘液获得基于弧菌属种子培养的河豚毒素（TTX）的可持续生物合成。 不可或缺的生物体保持活力，延长了对原料的使用，使得程序在经济和生态上是可持续的。

    Method of making genetically stable mutants of vibrio cholerae
    2.
    发明授权
    Method of making genetically stable mutants of vibrio cholerae 失效
    制作霍乱弧菌基因稳定突变体的方法

    公开(公告)号：US4264737A

    公开(公告)日：1981-04-28

    申请号：US59293

    申请日：1979-07-20

    申请人： John R. Murphy

    发明人： John R. Murphy

    IPC分类号： C12N15/01 ,  C12N15/00 ,  C12N1/36 ,  C12R1/63

    CPC分类号： A61K39/107 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  Y10S435/909

    摘要： Incubation of a parent strain of Vibrio cholerae at elevated temperature to produce a hypotoxinogenic variant strain and mutation of the variant strain results in mutant strains which retain the biotype and antigens of the parent strain, and which are genetically stable and useful as live oral vaccines for immunization against cholera. Preferably, a hypotoxinogenic mutant which is also non-pathogenic in animal model systems is isolated by the method disclosed in this application.

    摘要翻译： 在升高的温度下孵育霍乱弧菌的亲本菌株以产生低致毒性变体菌株和变异菌株的突变导致保留亲本菌株的生物型和抗原的突变菌株，并且它们作为活口服疫苗是基因稳定和有用的 免疫接种霍乱。 优选地，在动物模型系统中也是非致病性的低毒性突变体通过本申请中公开的方法分离。

    Deletion mutants of cholera vaccines expressing heterologous antigens
    4.
    发明授权
    Deletion mutants of cholera vaccines expressing heterologous antigens 失效
    表达异源抗原的霍乱疫苗的缺失突变体

    公开(公告)号：US5874088A

    公开(公告)日：1999-02-23

    申请号：US367115

    申请日：1995-01-05

    申请人： John J. Mekalanos

    发明人： John J. Mekalanos

    IPC分类号： A61P31/00 ,  A61P37/04 ,  C07K14/28 ,  C07K14/72 ,  C12N1/21 ,  C12N15/01 ,  A61K39/106

    CPC分类号： A61K39/107 ,  C07K14/28 ,  C07K14/72 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  A61K2039/542 ,  C07K2319/00 ,  Y10S435/909

    摘要： The invention features a nontoxigenic genetically stable mutant strain of V. cholerae which lacks any functional attRS1 sequences is useful as a live, oral vaccine for inducing immunological protection against cholera and a method for making same. The invention also features a killed, oral cholera vaccine comprising at least a first and a second V. cholerae strain, wherein at least one of the strains is a different serotype, and the vaccine also contains cholera toxin B subunit, produced by at least one of the serotypes.

    摘要翻译： PCT No.PCT / US93 / 06270 Sec。 371日期：1995年6月28日 102（e）日期1995年6月28日PCT提交1993年7月1日PCT公布。 第WO94 / 01533号公报 日期1994年1月20日本发明特征在于一种无毒基因遗传稳定的霍乱弧菌突变菌株，其缺乏任何功能性attRS1序列可用作诱导针对霍乱的免疫保护的活的口服疫苗及其制备方法。 本发明还具有包含至少第一和第二霍乱弧菌菌株的杀死的口服霍乱疫苗，其中至少一种菌株是不同的血清型，并且疫苗还含有由至少一种产生的霍乱毒素B亚基 的血清型。

    Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
    6.
    发明授权
    Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof 失效
    霍乱弧菌01（CVD111）和非01（CVD112和CVD112RM）血清群疫苗株，其制备方法及其产物

    公开(公告)号：US5882653A

    公开(公告)日：1999-03-16

    申请号：US624601

    申请日：1996-07-29

    申请人： James B. Kaper ,  Myron M. Levine

    发明人： James B. Kaper ,  Myron M. Levine

    IPC分类号： C07K14/28 ,  C12N15/01 ,  A61K39/106 ,  C12N1/20

    CPC分类号： A61K39/107 ,  C07K14/28 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  Y10S435/909

    摘要： Avirulent Vibrio cholerae strains of O1 (CVD111) and non-O1 (CVD112 and CVD112RM) serogroups having the DNA of the cholera toxin core and the RS1 sequences of the cholera toxin locus deleted, and further having a DNA encoding a resistance to mercury, and a DNA encoding the cholera toxin B subunit, or a part thereof sufficient to confer immunogenicity, re-inserted in the chromosome. Methods of making the avirulent V. cholerae O1 and non-O1 strains of the invention, and cholera vaccines using these strains.

    摘要翻译： PCT No.PCT / US94 / 11424 Sec。 371日期：1996年7月29日 102（e）日期1996年7月29日PCT 1994年10月7日PCT PCT。 出版物WO95 / 10300 日期：1995年4月20日具有霍乱毒素核心DNA和霍乱毒素基因座的RS1序列的O1（CVD111）和非O1（CVD112和CVD112RM）血清群的无毒性霍乱弧菌菌株缺失，并且还具有编码 对汞的抗性，以及编码霍乱毒素B亚基的DNA或其部分足以赋予免疫原性的DNA重新插入到染色体中。 制备本发明的无毒性霍乱弧菌O1和非O1菌株的方法，以及使用这些菌株的霍乱疫苗。

    Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof
    7.
    发明授权
    Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof 失效
    在霍乱弧菌中分离限制性片段缺失的方法及其产物

    公开(公告)号：US5470729A

    公开(公告)日：1995-11-28

    申请号：US931943

    申请日：1992-08-12

    申请人： James B. Kaper ,  Bernadette Baudry-Maurelli ,  Alessio Fasano

    发明人： James B. Kaper ,  Bernadette Baudry-Maurelli ,  Alessio Fasano

    IPC分类号： C07K14/28 ,  C12N15/01 ,  A61K35/74 ,  C12N1/21 ,  C12N15/63 ,  C12R1/63

    CPC分类号： A61K39/107 ,  C07K14/28 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  Y10S435/909

    摘要： Methods of isolating deletion mutants of Vibrio cholerae. In one method, the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. In another method, an initial in vivo recombination event of homologous sequences from the recombinant plasmid into the chromosome provides a selectable marker at this site. A second in vivo recombination event between homologous flanking sequences results in excision of proficient genes from the chromosome with the end product being a deletion mutation. Also provided are methods for the isolation and characterization of a new Vibrio cholerae strain having a deletion in the ctx gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites and further having a deletion in the gene encoding zonula occludens toxin (zot).

    摘要翻译： 分离霍乱弧菌缺失突变体的方法。 在一种方法中，通过用已知特异性的限制性内切核酸酶消化来预先确定缺失。 通过携带所需缺失的质粒与相邻侧翼序列和霍乱弧菌染色体之间的体内重组将缺失插入霍乱弧菌染色体。 在另一种方法中，从重组质粒到染色体的同源序列的初始体内重组事件在该位点提供可选择的标记。 同源侧翼序列之间的第二次体内重组事件导致了染色体上的精通基因的切除，最终产物是缺失突变。 还提供了用于分离和表征由Acc I，Xba I，Cla I和/或限制性内切核酸酶位点定义的ctx基因中缺失的新的霍乱弧菌菌株的方法，并且在编码区域的基因中还具有缺失 闭塞毒素（zot）。

    Vibrio cholerae strain CVD103Hg.sup.r, method of making same, and vaccines derived therefrom
    8.
    发明授权
    Vibrio cholerae strain CVD103Hg.sup.r, method of making same, and vaccines derived therefrom 失效
    霍乱弧菌菌株CVD103Hgr，其制备方法和由其衍生的疫苗

    公开(公告)号：US5399494A

    公开(公告)日：1995-03-21

    申请号：US936829

    申请日：1992-08-28

    申请人： James B. Kaper ,  Myron M. Levine

    发明人： James B. Kaper ,  Myron M. Levine

    IPC分类号： C07K14/28 ,  C12N1/21 ,  C12N15/01 ,  C12N15/03 ,  C12N15/31 ,  C12R1/63

    CPC分类号： A61K39/107 ,  C07K14/28 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  Y10S435/909

    摘要： Method of isolating deletion mutants of Vibrio cholerae, wherein the deletion is predetermined by digestion with restriction endonucleases of known specificity. The deletions are inserted into the Vibrio cholerae chromosome by in vivo recombination between a plasmid carrying the desired deletion, with adjacent flanking sequences, and the Vibrio cholerae chromosome. The invention includes the isolation and characterization of a new Vibrio cholerae strain, (ATCC No. 55456), having a deletion in the tox gene, as defined by Acc I, Xba I, Cla I and/or restriction endonuclease sites, and carrying a mercury resistance gene. The invention also includes vaccines for protecting against the symptoms of cholera as well as methods for achieving this protection.

    摘要翻译： 分离霍乱弧菌的缺失突变体的方法，其中通过用已知特异性的限制性核酸内切酶消化来预先确定缺失。 通过携带所需缺失的质粒与相邻侧翼序列和霍乱弧菌染色体之间的体内重组将缺失插入霍乱弧菌染色体。 本发明包括分离和表征新的霍乱弧菌菌株（ATCC No.55456），其在由Acc I，Xba I，Cla I和/或限制性内切核酸酶位点定义的tox基因中具有缺失，并携带 耐汞基因。 本发明还包括用于防止霍乱症状的疫苗以及用于实现该保护的方法。

    Cholera vaccine
    9.
    发明授权
    Cholera vaccine 失效
    霍乱疫苗

    公开(公告)号：US4328209A

    公开(公告)日：1982-05-04

    申请号：US29092

    申请日：1979-04-11

    申请人： Richard A. Finkelstein ,  Takeshi Honda

    发明人： Richard A. Finkelstein ,  Takeshi Honda

    IPC分类号： C12N1/20 ,  A61K39/106 ,  C12N15/01 ,  C12N15/00 ,  C12N1/36 ,  C12R1/63

    CPC分类号： A61K39/107 ,  C12N15/01 ,  C12R1/63 ,  A61K2039/522 ,  Y10S435/909

    摘要： Vibrio cholerae, Ogawa serotype, El Tor biotype, are subjected to the mutagenic N-methyl-N'-nitro-n-nitrosoguanidine (NTG). First generation mutants are screened for toxin production, and in particular the absence of "A" or enzymatically active subunit production and production of B (binding) subunit. Putative A.sup.- B.sup.+ mutants are again exposed to NTG and screened for the A.sup.- B.sup.+ characteristics. The formula of the native toxin molecule is usually A.sup.+ B.sup.+.sub.5-6, the formula for the molecule produced by the selected second generation mutant is A.sup.- B.sup.+.sub.5-6. This mutant strain is used for production of a live attenuated vaccine which can be administered orally. The mutant has been found to induce immunity, in an experimental model system, against subsequent challenge with virulent cholera vibrios. Because of the immunologic relationship to other enterotoxins (such as the heat-labile enterotoxin of Escherichia coli), the mutant may also induce immunity to diarrheal diseases other than cholera. In fact, antiserum to the isolated toxin-related protein produced by the mutant has been shown to neutralize E. coli entero-toxin. The mutant may also be used for the production of "choleragenoid", the non-toxic, highly immunogenic B portion of the cholera enterotoxin (choleragen) without the complication of toxicity associated with the complete enterotoxin.

    摘要翻译： 将霍乱弧菌，Ogawa血清型，El Tor生物型进行诱变的N-甲基-N'-硝基-N-亚硝基胍（NTG）。 筛选第一代突变体用于毒素生产，特别是没有“A”或酶活性亚基生产和生产B（结合）亚基。 推定的A-B +突变体再次暴露于NTG并筛选A-B +特征。 天然毒素分子的配方通常为A + B + 5-6，所选择的第二代突变株产生的分子式为A-B + 5-6。 该突变菌株用于生产可以口服给药的活减毒疫苗。 已经发现该突变体在实验模型系统中诱导免疫，以抵抗随后的毒性霍乱弧菌的攻击。 由于与其他肠毒素（如大肠杆菌的热不稳定肠毒素）的免疫关系，突变体也可能诱导除霍乱以外的腹泻疾病的免疫。 实际上，由突变体产生的分离的毒素相关蛋白质的抗血清已显示中和大肠杆菌肠毒素。 该突变体还可用于生产霍乱肠毒素（霍乱）的无毒，高度免疫原性B部分的“霍乱胆固醇”，而没有与完全肠毒素相关的毒性并发症。